ALX Oncology Q2 FY26 GAAP net loss narrows to $18 million; R&D expenses fall 27.2% to $13.1 million

Reuters2026/08/06 12:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ALX Oncology posted a GAAP net loss of USD 18 million, narrowing from USD 25.9 million a year earlier; loss per share improved to USD 0.13 from USD 0.49.
R&D expense fell 27.22% to USD 13.1 million on lower clinical and development costs, partly offset by investment in ASPEN-09 and ALX2004.
Cash, cash equivalents and investments climbed to USD 153.4 million; the company expects this to fund operations through 1H 2028.
ASPEN-09-Breast Phase 2 topline data from 80 patients remains slated for mid-2027; ALX2004 Phase 1 enrollment continues with initial safety data due in 2H 2026.
CEO Jason Lettmann cited “strong enrollment momentum” for ALX2004 and said the ESMO Breast Cancer data supports evorpacept’s biomarker-driven strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ALX Oncology Q2 FY26 GAAP net loss narrows to $18 million; R&D expenses fall 27.2% to $13.1 million

You may also like

Crypto prices